Daniell Richard, EVP of Europe Commercial at Teva Pharmaceutical Industries (TEVA), has been a consistent seller of company stock over the past year, with SEC Form 4 filings showing 46 total transactions and zero open-market purchases. The aggregate sell value across his reported activity reached approximately $18.6 million, with all trades concentrated in a single ticker. The recent pattern is unambiguous: 14 sales in the most recent period, no buys, and a heavy cluster of dispositions in early March 2026.
The selling accelerated in the first week of March 2026, when Richard executed multiple open-market sales totaling roughly $7.7 million. On March 3 alone, he disposed of shares worth $2.16 million and $2.01 million, followed by three separate sales on March 4 totaling about $2.98 million, and a further $547,705 on March 5. These transactions were paired with option exercises (coded M) valued at zero, indicating the sales were tied to the conversion of existing awards rather than new cash purchases. The largest single disposition came earlier, on December 9, 2025, when Richard sold $3.31 million in TEVA shares, alongside option exercises valued at $2.12 million.
The data shows no acquisition activity—no open-market buys (code P), no grants with positive value, and no purchases of any kind. Richard's sales have been steady but not uniform: a $887,195 sale on March 4, 2025, was followed by a cluster of five smaller sales on March 5, 2025, totaling roughly $1.9 million. The most recent filing, dated May 5, 2026, shows a $1.06 million sale, confirming the selling bias has persisted into the current quarter. All transactions involve TEVA, and the absence of any buy-side activity across 46 filings points to a consistent, one-directional pattern of insider liquidation.
AI-assisted summary